Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
March 13, 2025Pamplona/MadridIn recruitment
C1071006 Trial of elranatamab in participants with newly diagnosed multiple myeloma ineligible for transplantation.
The goal of Part 1 is to find the best dose of elranatamab (also known as PF-06863135) and lenalidomide when given in combination with another drug called daratumumab for use in Part 2 and to learn about the safety and effects of this combination on the body. Elranatamab, daratumumab and lenalidomide are study drugs that are not approved for use in combination. -
March 10, 2025Pamplona/MadridIn recruitmentEarly phase
U31402-A-U102 Multicenter, open-label, phase I clinical trial of U3-1402 in subjects with unresectable or metastatic non-small cell lung cancer.
The purpose of this consent form is to obtain your permission for the release of previously collected tumor tissue (archival tissue) following the growth of your tumor while you were taking your previous cancer medication. -
March 6, 2025Pamplona/MadridIn recruitmentEarly phase
EF-50 Tumor Treatment Clinical Trial (TTFields, 150 kHz) with pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy
The aim of this study is to evaluate the efficacy and safety of TTFields therapy together with pembrolizumab (a common immunotherapy agent). -
March 5, 2025MadridIn recruitmentEarly phase
222730 Phase I clinical trial to evaluate drug GSK5733584 in participants with advanced solid tumors
The aim of this study is to evaluate the safety, tolerability, pharmacokinetics and anticancer activity of GSK5733584. -
March 3, 2025PamplonaIn recruitment
GS-US-595-6184 Clinical trial of adjuvant sacituzumab, govitecan and pembrolizumab versus treatment in patients with triple negative breast cancer.
In this clinical research study, the experimental treatment, which is a combination of sacituzumab govitecan and pembrolizumab, will be tested. -
March 3, 2025Pamplona/MadridIn recruitment
PRISM-1 Multicenter, randomized, placebo-controlled, double-masked, multicenter phase III clinical trial of quemliclustat and chemotherapy compared to placebo and chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.
The aim of this study is to determine whether the study drugs, quemliclustat (also known as AB680) in combination with gemcitabine and nab-paclitaxel chemotherapy (Gem-NP), compared to a placebo (saline solution containing no active ingredients) in combination with gemcitabine and nab-paclitaxel chemotherapy, would be safe and effective in treating patients with the type of cancer they have. -
February 25, 2025Pamplona/MadridIn recruitment
IELSG48 Phase 3 clinical trial comparing rituximab plus zanubrutinib with rituximab monotherapy in previously untreated symptomatic splenic marginal zone lymphoma
The aim of this clinical trial is to compare the efficacy and tolerability of the combination of two drugs, rituximab and zanubrutinib, compared to rituximab monotherapy in patients with previously untreated splenic marginal zone lymphoma (SMZL) requiring systemic treatment. -
February 24, 2025Pamplona/MadridIn recruitment
D7020C00001 Clinical trial of the anti-TIGIT/anti-PD-1 bispecific antibody AZD2936 in patients with advanced or metastatic non-small cell lung cancer.
The objective of this study is to learn more about AZD2936, a new antibody that blocks two proteins (PD-1 and TIGIT) at the same time. AZD2936 can be used if unresectable or metastatic non-small cell lung cancer has been diagnosed. The main objective of this study is to gather information on the correct dose of AZD2936 and to understand whether this new drug can be useful for the treatment of the diagnosed disease. Both PD-1 and TIGIT are called "immune checkpoints". They emit signals ... -
February 18, 2025Pamplona/MadridIn recruitment
D8470C00001 Phase I/IIa clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AZD8421 alone or in combination in patients with selected advanced or metastatic solid tumors (CYCAD-1)
El objetivo es investigar la seguridad y tolerabilidad, caracterizar los DLT y determinar la DMT y/o DMF y/o dosis recomendada dosis recomendada de fase II (RP2D) de AZD8421 como monoterapia y también en combinación con otros medicamentos contra el cáncer. -
February 18, 2025PamplonaIn recruitment
IVY-P3-24-021 Phase III, open-label, randomized, 2-group clinical trial to compare the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly diagnosed MGMT-unmethylated glioblastoma
This is a Phase III trial. This trial includes: Phase 1, in which the trial drug or comparator drug will be taken and all participants will also receive radiotherapy; and Phase 2, in which they will continue with the same drug they were given in Phase 1 without radiotherapy.